Published: 2023-04-27
BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, today publishes the interim report for the first quarter 2023.
CONTINUED STRONG GROWTH
JANUARY – MARCH 2023
- Net sales increased by 80 percent (66 percent at constant exchange rates) and amounted to SEK 119.7 million (66.3).
- The North America (NA) segment reported a sales growth of 109 percent (87 percent at constant exchange rate).
- The Europe & Rest of the World (EUROW) segment reported a sales growth of 34 percent (32 percent at constant exchange rates).
- The gross margin amounted to 90.5 percent (90.5).
- Operating result before effects from the Group’s incentive programs amounted to SEK +4.6 million (-12.5). Reported operating result amounted to SEK +0.8 million (-16.5).
- Earnings per share, before and after dilution, were SEK +0.00 (-0.32).
"Strong sales growth driven by CERAMENT G in the US." Emil Billbäck, CEO
EVENTS DURING THE REPORTING PERIOD
The FDA has announced that the label extension application for CERAMENT G, to include open fracture/trauma, should be made within the 510(k) regulatory framework and not within the De Novo regulatory framework.
EVENTS AFTER THE REPORTING PERIOD
Nothing to report.